Biotech Daily Home
|
Biotech Daily covers the major announcements from more than 140 ASX-listed biotech companies as well as the major research institutes and developments in government policy. Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector. The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter. Base-rate subscriptions are $A1600 a year (including GST in Australia). Subscribers include biotech directors and CEOs, major pharmaceutical companies, universities, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.
|
|
Victoria: 'Funding Returns 366% GSP, 454% Income In 10 Years' Kazia $382m+ Simcere Paxalisib Brain Cancer China Deal Dr Boreham's Crucible: Anteotech A Year In The Grass - Medical Marijuana Review Budget 2020 Special Edition; Comment & Analysis Cyclopharm: US Technegas Trial Meets Endpoints Early Biotech Daily 1st Medical Marijuana Survey CSIRO, Doherty Distance From 'Tier 1' Sars-Cov-2 Claims Biotech Daily Editorial: Covid-19 Spruikers, Please Stop ! All the Dope on Medicine, Marijuana, Cannabis & Hemp
April BDI-40 Up 7% To Record $19.7b Optiscan Up 115%, Actinogen 69%, Imugene 59%; Mesoblast Down 16% May 3, 2021 The benchmark S&P ASX200 was up 3.5 percent to 7,026 points, up 27.2 percent compared to 12 months ago, but still below the pre-Covid 7,017 points (see charts below).
The BDI-40 was 17.5 percent above its pre-Covid record high and 39.9 percent above April 30, 2020 (see charts below).
The collective market capitalization of the three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) was up 3.7 percent in April, with Cochlear up 6.5 percent to $14,774 million, Resmed up 3.6 percent to $38,079 million and CSL up 3.3 percent to $124,471 million.
For the 12 months to April 30, the Big Caps were down 0.6 percent.
In the US, the Nasdaq Biotech Index (NBI) climbed 3.0 percent in April, 24.7 percent above April 30, 2020.
Twenty-one of the BDI-40 stocks were up, 11 by more than 10 percent; 17 companies fell in April, seven by more than 10 percent; with two unchanged.
It was a tale of two indices, with the Second 20 seeing some extraordinary rises from small bases. Last month’s 91.2 percent best, Actinogen, was second best in April to Optiscan’s 114.7 percent jump to $277 million, eclipsing Actinogen’s 69.2 percent rise to $110 million.
Imugene was up 58.8 percent to $907 million, Universal Biosensors was up 40.7 percent and Next Science improved 29.8 percent, with Pharmaxis the best of the Top 20, up 18.75 percent, followed by Pro Medicus (14.3%), Immutep (13.6%), Polynovo (12.6%), Amplia (10.7%) and Clinuvel (10.5%).
Mesoblast led the falls, down 15.7 percent to $1,187 million, followed by Telix (12.6%), Genetic Signatures (11.7%), Prescient (11.4%), Patrys (11.3%), Starpharma (10.8%) and Kazia (10.4%).
Outside the BDI-40, Anteo was the star, up 74.1 percent to $815 million, with Alcidion and Emvision continuing strong growth and three marijuana companies – Creso, Ecofibre and Incannex – also impressing.
The 22 companies in Cannabis Corner were up 10.8 percent to a collective market capitalization of $1,973 million, eclipsing the February record high of $1,945 million.
On the Nasdaq, Queensland’s Protagonist climbed a further 10.2 percent to $1,647, - 475.9 percent above April 30, 2020. Eyepoint (formerly Psivida) was up 3.6 percent to $398 million and Redhill (with Australian assets) fell eight percent to $412 million.
BDI-40 v S&P ASX200 Jun 30, 2006 to Apr 30, 2021
 5-Year Big Caps (Cochlear, CSL, Resmed) to Apr 30, 2021
 BDI-40 ($m) v S&P ASX200 – Jan 31, 2020 - Apr 30, 2021
(current, raw data) 
|
Click here for Biotech Daily's archive
Biotech Daily Top 40 With Market Capitalization At Apr 30, 2021
* Biotech Daily editor, David Langsam, owns shares in Acrux, Actinogen, Alcidion, Alterity, Amplia, BTC Health, Cochlear
Control Bionics, Cynata, Nanosonics, Neuren, Patrys, Polynovo, Telix and Volpara, as well as non-biotechnology stocks.
Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies.
These holdings are liable to change:
https://www.australianethical.com.au/personal/ethical-investing/companies-we-invest-in/.